Literature DB >> 25400395

Successful use of N-acetyl cysteine and activated recombinant factor VII in fulminant hepatic failure and massive bleeding secondary to dengue hemorrhagic fever.

Edirisooriya Maddumage Manoj1, Gayan Ranasinghe1, M K Ragunathan1.   

Abstract

Consensus on management of complicated cases of dengue infection is evolving. Dengue hemorrhagic fever (DHF) occasionally progress to fulminant liver failure with high fatality rate. Inadvertent use of blood products to control massive bleeding in dengue shock syndrome may worsen fluid overload and subsequently the multi-organ dysfunction. We report a case of 37-years-old Sri Lankan man who developed fulminant liver failure and massive bleeding associated with DHF, subsequently recovered completely with supportive measures including administration of N-acetyl cysteine and activated recombinant factor VII. In conclusion, prevention of ischemic injury to liver and adoption of early aggressive supportive measures in complicated cases of dengue hemorrhagic fever is crucial for a favorable outcome. Indications for rFVIIa to arrest uncontrolled internal bleeding and use of NAC in non-acetaminophen-induced acute liver failure in complicated DHF are a platform for discussion.

Entities:  

Keywords:  Activated recombinant factor VII; N-acetyl cysteine; dengue; fulminant hepatic failure

Year:  2014        PMID: 25400395      PMCID: PMC4231270          DOI: 10.4103/0974-2700.142771

Source DB:  PubMed          Journal:  J Emerg Trauma Shock        ISSN: 0974-2700


  13 in total

Review 1.  Pathogenesis of liver involvement during dengue viral infections.

Authors:  S L Seneviratne; G N Malavige; H J de Silva
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-02-17       Impact factor: 2.184

Review 2.  A travel medicine view of dengue and dengue hemorrhagic fever.

Authors:  Eyal Meltzer; Eli Schwartz
Journal:  Travel Med Infect Dis       Date:  2009-07-22       Impact factor: 6.211

3.  Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients.

Authors:  Ampaiwan Chuansumrit; Sumate Teeraratkul; Suthep Wanichkul; Suporn Treepongkaruna; Nongnuch Sirachainan; Samart Pakakasama; Pracha Nuntnarumit; Suradej Hongeng
Journal:  Blood Coagul Fibrinolysis       Date:  2010-06       Impact factor: 1.276

Review 4.  Use of clotting factors and other prohemostatic drugs for obstetric hemorrhage.

Authors:  Frédéric J Mercier; Marie-Pierre Bonnet
Journal:  Curr Opin Anaesthesiol       Date:  2010-06       Impact factor: 2.706

Review 5.  A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.

Authors:  Z H Yuan; J K Jiang; W D Huang; J Pan; J Y Zhu; J Z Wang
Journal:  J Clin Neurosci       Date:  2010-06       Impact factor: 1.961

6.  N-acetylcysteine in acute hepatic failure (non-paracetamol-induced).

Authors:  Z Ben-Ari; H Vaknin; R Tur-Kaspa
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

7.  Fulminant hepatitis in dengue haemorrhagic fever.

Authors:  L M Ling; A Wilder-Smith; Y S Leo
Journal:  J Clin Virol       Date:  2007-02-15       Impact factor: 3.168

8.  Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.

Authors:  William M Lee; Linda S Hynan; Lorenzo Rossaro; Robert J Fontana; R Todd Stravitz; Anne M Larson; Timothy J Davern; Natalie G Murray; Timothy McCashland; Joan S Reisch; Patricia R Robuck
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

9.  Dengue hemorrhagic fever and fulminant hepatic failure.

Authors:  Venkataraman Subramanian; Suresh Shenoy; Anjelivelil J Joseph
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.487

10.  Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.

Authors:  Sandro B Rizoli; Kenneth D Boffard; Bruno Riou; Brian Warren; Philip Iau; Yoram Kluger; Rolf Rossaint; Michael Tillinger
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more
  5 in total

1.  The outcomes of patients with severe dengue admitted to intensive care units.

Authors:  Chin-Ming Chen; Khee-Siang Chan; Wen-Liang Yu; Kuo-Chen Cheng; Hui-Chun Chao; Chiu-Yin Yeh; Chih-Cheng Lai
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

2.  COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?

Authors:  Marie-Pierrette Ntyonga-Pono
Journal:  Pan Afr Med J       Date:  2020-04-29

3.  Melatonin Inhibits Dengue Virus Infection via the Sirtuin 1-Mediated Interferon Pathway.

Authors:  Atthapan Morchang; Shilu Malakar; Kanchanaphan Poonudom; Sansanee Noisakran; Pa-Thai Yenchitsomanus; Thawornchai Limjindaporn
Journal:  Viruses       Date:  2021-04-11       Impact factor: 5.048

Review 4.  N-acetylcysteine for non-acetaminophen induced acute liver failure: A review.

Authors:  Shirley Xue Jiang; Trana Hussaini; Eric M Yoshida
Journal:  Saudi J Gastroenterol       Date:  2022 Mar-Apr       Impact factor: 2.485

Review 5.  Repurposing of N-Acetylcysteine for the Treatment of Dengue Virus-Induced Acute Liver Failure.

Authors:  Gebrehiwot Gebremedhin Tafere; Dawit Zewdu Wondafrash; Filmon Beyenne Demoz
Journal:  Hepat Med       Date:  2020-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.